| Description |
1 online resource (235 pages) |
| Series |
WHO Technical Report Series |
|
Technical report series (World Health Organization)
|
| Contents |
Cover; Contents; Executive summary; List of participants; Declarations of interests; 1. Introduction; 2. Open session; 3. General items; 3.1 Defining public health relevance; 3.2 Medicines information as a global public good; 3.3 Other; 4. Applications only for paediatric medicines; Section 1: Anaesthetics; Anaesthetics (review) -- Children; Section 2: Non-steroidal anti-inflammatory medicines (NSAIMs) and medicines used to treat gout and disease-modifying agents in rheumatoid disorders (DMARDs); 2.2: Opioid analgesics; Section 6: Anti-infective medicines; 6.2: Antibacterials |
|
6.4: Antiviral medicines6.5: Antiprotozoal medicines; Section 8: Antineoplastics; 8.4: Medicines used in palliative care; Section 11: Blood products and plasma substitutes; 11.1: Plasma substitutes; Section 12: Cardiovascular medicines; 12.2: Antiarrhythmic medicines; 12.6: Lipid-lowering agents; Section 15: Disinfectants and antiseptics; 15.1: Antiseptics; Section 24: Medicines for mental and behavioural disorders; 24.1: Medicines used in psychotic disorders; 24.2: Medicines used in mood disorders; Section 28: Ear, nose and throat medicines; Section 29: Specific medicines for neonatal care |
|
5. Applications for the 18th Model List and the 4th EMLcSection 2: NSAIMs and DMARDs; 2.1: Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs); 2.3: Medicines used to treat gout; Section 3: Antiallergics and medicines used in anaphylaxis; Section 4: Antidotes and other substances used in poisonings; Section 6: Anti-infective medicines; 6.2: Antibacterials; 6.3: Antifungal medicines; 6.4: Antiviral medicines; 6.5: Antiprotozoal medicines; Section 8: Antineoplastics, immunosuppressives and medicines used in palliative care; 8.2: Cytotoxic and adjuvant medicines |
|
8.4: Medicines used in palliative careSection 9: Antiparkinsonism medicines; Section 10: Medicines affecting the blood; 10.1: Antianaemia medicines; Section 11: Blood products and plasma substitutes; 11.2: Plasma fractions for specific use; Section 12: Cardiovascular medicines; 12.4: Medicines used in heart failure; Section 13: Dermatological medicines (topical); 13.4: Medicines affecting skin differentiation and proliferation; Section 17: Gastrointestinal medicines; 17.1: Antiulcer medicines; Section 18: Hormones, other endocrine medicines and contraceptives |
|
18.5: Insulins and other medicines used for diabetesSection 21: Ophthalmological preparations; Section 22: Oxytocics and antioxytocics; 22.1: Oxytocics; Section 24: Medicines for mental and behavioural disorders; 24.1: Medicines used in psychotic disorders; 24.2: Medicines used in mood disorders; Section 27: Vitamins and minerals; Section 28: Ear, nose and throat medicines; 6. Summary of recommendations; 18th WHO Model List of Essential Medicines; 4th Essential Medicines List for Children; Recommendations for reviews; References; Annex 1 18th WHO Model List of Essential Medicines (April 2013) |
| Summary |
This report presents the recommendations of the WHO Expert Committee responsible for updating the WHO Model Lists of Essential Medicines. It contains a summary of the Committee's considerations and justifications for additions and changes to the Model Lists including its recommendations. Annexes to the main report include the revised version of the WHO Model List of Essential Medicines (18th edition) and the WHO Model List of Essential Medicines for Children (4th edition). In addition there is a list of all the items on the Model Lists sorted according to their Anatomical Therapeutic Chemical |
| Notes |
Annex 2 4th WHO Model List of Essential Medicines for Children (April 2013) |
|
Print version record |
| Subject |
Drug utilization -- Congresses
|
|
Drug utilization.
|
| Genre/Form |
Conference papers and proceedings.
|
| Form |
Electronic book
|
| ISBN |
9789240692251 |
|
9240692258 |
|
